CD8A and Immunodeficiency: After heart transplantation, many patients will have broad immune deficiency and the immunological status of the patient is likely to contribute to the difficulty in controlling any subsequent CMV disease. When considering use of CMVIG, lack of CMV‐specific T cells, presence of HGG, CD4+/CD8+ or NK lymphocytopenia could all suggest high risk of disease. The tools to assess these factors are accessible in most clinics based on feedback provided by delegates during the case discussion.